Clinical Study Results, Approvals, Financial Results, New Facilities, and Business Expansions - Research Report on Merck,
Clinical Study Results, Approvals, Financial Results, New Facilities, and Business Expansions - Research Report on Merck, UnitedHealth Group, NPS Pharmaceuticals, Abbott, and Medtronic Editor Note: For more information about this release, please scroll to bottom. PR Newswire NEW YORK, November 11, 2013 NEW YORK, November 11, 2013 /PRNewswire/ -- Today, Analysts' Corner announced new research reports highlighting Merck & Co., Inc. (NYSE: MRK), UnitedHealth Group Inc. (NYSE: UNH), NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), Abbott Laboratories (NYSE: ABT), and Medtronic, Inc. (NYSE: MDT). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Merck & Co., Inc. Research Report On November 4, 2013, Merck & Co., Inc. (Merck) announced that in the Phase III efficacy study, its investigational 9-valent HPV vaccine (V503) prevented approximately 97.0% of cervical, vaginal and vulvar pre-cancers caused by HPV types 31, 33, 45, 52, and 58. The Company stated that V503 also generated immune responses to HPV types 6, 11, 16, and 18 that were non-inferior to those generated by GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant]. Roger M. Perlmutter, M.D., Ph.D., President of Merck Research Laboratories, commented, "With our ongoing commitment to research, we are building upon the success obtained with GARDASIL, and we expect to submit a Biologics License Application for V503 to the U.S. Food and Drug Administration before the end of 2013." The Full Research Report on Merck & Co., Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [ http://www.analystscorner.com/r/full_research_report/430d_MRK ] -- UnitedHealth Group Inc. Research Report On October 30, 2013, UnitedHealth Group Inc. (UnitedHealth Group) reported that UnitedHealthcare Community Plan - a business unit of its subsidiary, UnitedHealthcare, has expanded its service area to include eight New York State counties namely: Albany, Chautauqua, Chemung, Columbia, Essex, Genesee, Niagara, and St. Lawrence, where it offers the New York State Medicaid, Family Health Plus and Child Health Plus plans. The Company informed that UnitedHealthcare's New York State Medicaid, Family Health Plus, and Child Health Plus plans are now available in New York City, on Long Island, in the Hudson Valley, and throughout Central and Western New York. UnitedHealth Group added that with this expansion, UnitedHealthcare Community Plans are now available in 34 New York counties. The Full Research Report on UnitedHealth Group Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [ http://www.analystscorner.com/r/full_research_report/73e5_UNH ] -- NPS Pharmaceuticals, Inc. Research Report On November 6, 2013, NPS Pharmaceuticals, Inc. (NPS Pharmaceuticals) reported its Q3 2013 financial results. Total revenues increased 45.1% YoY to $39.2 million during the quarter. Net loss was $1.1 million or $0.01 per diluted share in Q3 2013, compared to $3.3 million or $0.04 per diluted share in Q3 2012. Commenting on the results, Francois Nader, M.D., President and CEO at NPS Pharmaceuticals, said, "We are excited by the continued success of the Gattex launch in the U.S. We are seeing strong demand and sales have exceeded our expectations so far with 235 patients now on Gattex. We are also pleased to raise our full-year net sales guidance to $28 to $32 million given the favorable results and trends we have seen so far." The Full Research Report on NPS Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [ http://www.analystscorner.com/r/full_research_report/441a_NPSP ] -- Abbott Laboratories Research Report On November 6, 2013, Abbott Laboratories (Abbott) together with its foundation, the Abbott Fund, and Partners in Health (PIH) announced the opening of a new nutrition production facility to produce "Nourimanba," a life-saving treatment for severe malnutrition in children, in Central Plateau in Haiti. The Company stated that the first shipments of Nourimanba produced at the facility have been distributed in PIH's clinics in the region, and are already being used to provide effective treatment for children. Ophelia Dahl, PIH Co-Founder and Executive Director, commented, "After several years of close collaboration, we are excited to achieve this significant milestone in our partnership with Abbott and the Abbott Fund. Producing Nourimanba at the new facility will help PIH and Zanmi Lasante to continue providing free, high-quality treatment for children at our clinics across the region." The Full Research Report on Abbott Laboratories - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [ http://www.analystscorner.com/r/full_research_report/05c1_ABT ] -- Medtronic, Inc. Research Report On November 5, 2013, Medtronic, Inc. (Medtronic) announced that the U.S. Food and Drug Administration (FDA) has approved an Investigational Device Exemption (IDE), allowing the Company to initiate SYMPLICITY HTN-4, the first randomized trial to investigate renal denervation for the treatment of moderate uncontrolled hypertension in U.S. patients. Medtronic reported that the study will evaluate Symplicity™ renal denervation system in patients with moderate uncontrolled hypertension (systolic blood pressure greater than or equal to 140 and less than 160 mm HG, despite treatment with three or more anti-hypertensive medications of different classes). Nina Goodheart, Vice President, General Manager, Renal Denervation, Medtronic, commented, "SYMPLICITY HTN-4 builds upon our rigorous clinical evaluation of the Symplicity renal denervation system designed to carefully and progressively develop the clinical evidence platform for the treatment of hypertension." According to the Company, SYMPLICITY HTN-4, is Medtronic's second randomized, controlled renal denervation clinical trial in the United States. The Full Research Report on Medtronic, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [ http://www.analystscorner.com/r/full_research_report/bc94_MDT ] ---- EDITOR NOTES: 1. This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com . 5. For any urgent concerns or inquiries , please contact us at compliance@EquityNewsNetwork.com . 6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. AnalystsCorner.com Contact: CONTACT PERSON: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America).